Question explored with the scientific record
Do antibiotics work on Crohn's?
The short version: antibiotics can help some Crohn's situations, but the evidence is weak and the benefit often fades when you stop.
For active Crohn's, a pooled analysis of 15 trials found antibiotics beat placebo on clinical response, about 1.33 times the response rate [1]. But when they looked at ciprofloxacin for disease in the last part of the small intestine (ileum), it was no better than placebo [1]. So "antibiotics work" is not a clean yes.
The clearest real-world use is around surgery and fistulas. After surgery, a class of antibiotics called nitroimidazoles cut severe recurrence at 3 months and clinical recurrence at 12 months, with a number needed to treat of 4 for both [3]. That means treating 4 people prevents one bad outcome. For perianal fistulas, adding ciprofloxacin to adalimumab shrank fistulas in 24 of 34 people versus 17 of 36 on placebo, but the gap vanished once the antibiotic stopped [2].
The honest caveat: overall evidence quality is low. Only 4 of 25 trials had low risk of bias, and antibiotic trials were far smaller than biologic trials [4]. Antibiotics also carry their own risks, and one review notes they may even increase IBD risk [1].
| Situation | Antibiotic vs placebo | Notes |
|---|---|---|
| Active Crohn's, overall | 1.33x response | Pooled, 15 trials [1] |
| Ileal Crohn's (cipro) | No clear benefit | 1.15x, not significant [1] |
| Fistulas (cipro + adalimumab) | 24/34 vs 17/36 | Benefit lost after stopping [2] |
| Post-surgery recurrence | NNT of 4 | Within 90 days of surgery [3] |
My call: antibiotics are worth trying for perianal fistulas and just after surgery, not as a general treatment for active Crohn's. Confidence: moderate for those two uses, low for the rest.
Sources used 4
-
Practical Considerations and the Intestinal Microbiome in Disease: Antibiotics for IBD Therapy
This review finds antibiotic therapy can induce and maintain remission in IBD and prevent postoperative recurrence, but evidence quality is low, benefits are often transient, and antibiotics may increase IBD risk.
DOI: 10.1159/000443014 -
Prolonged disease remission of the chronic immunological skin disorder hidradenitis suppurativa with adjunctive bacteriophage therapy
A single-patient case report showing prolonged remission of hidradenitis suppurativa in a 52-year-old woman following adjunctive therapy with a patient-adapted bacteriophage (Prima HS) targeting Staphylococcus aureus, with substantial clinical improvement, reduced systemic infla…
DOI: 10.1038/s41467-025-65939-x -
Prospective observational study on Stelara (ustekinumab) assessing effectiveness in Crohn’s disease (PROSE): a 16-week follow-up
A nation-wide Swedish prospective real-world study evaluating short-term effectiveness and safety of ustekinumab for Crohn's disease, showing 24% clinical response and 26% clinical remission at 16 weeks with improvements in CRP and faecal calprotectin and no major safety signals.
DOI: 10.1080/00365521.2021.1906946 -
P556 Long-term probability of retreatment with anti-TNF therapy after discontinuation based on mucosal healing in inflammatory bowel disease
Discontinuation of anti-TNF therapy after mucosal healing in inflammatory bowel disease leads to relapse in a substantial proportion of patients, with reintroduction achieving measurable response rates and varying by disease type and pattern.
DOI: 10.1093/ecco-jcc/jjz203.684